viewTissue Regenix Group PLC

Tissue Regenix chief: Commercialisation now key

Antony Odell, chief executive of Tissue Regenix (LON:TRX), discusses the company’s commercialisation push for its advanced wound care product.

Today, the AIM-listed group revealed it will be sharing the latest data on DermaPure with some of the industry’s leading professionals at the Symposium for Advanced Wound Care’s spring meeting in the US.

It follows the news of a ‘critical step’ towards regulatory sign-off for the start of clinical trials for Orthopure XT, a decellularised tendon device for the reconstruction of a torn anterior cruciate ligament – a career-threatening injury for footballers and other athletes.

Quick facts: Tissue Regenix Group PLC

Price: 0.37 GBX

Market: AIM
Market Cap: £26.02 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...


Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read